Cancer Advances, Inc. Announces Issuance of New U.S. Patent
February 28, 2023 02:00 ET
|
Cancer Advances Inc
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....
The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035, claims Roots Analysis
March 09, 2022 09:30 ET
|
Roots Analysis
London, March 09, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035” report to its list of offerings. Given the various...
Cancer Advances, Inc. Announces Publication, “Vaccination with Polyclonal Antibody Stimulator (PAS) Prevents Pancreatic Carcinogenesis in the KRAS Mouse Model" in Cancer Prevention Research
August 24, 2021 10:30 ET
|
Cancer Advances Inc
DURHAM, N.C., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces a new publication in...
Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
May 19, 2021 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...
Cancer Advances, Inc. Announces Poster Presentation at ASCO GI
January 21, 2020 22:20 ET
|
Cancer Advances Inc
DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...
Key Patent Issued on Qantu's QT-0101 Adjuvant
February 25, 2019 05:00 ET
|
QANTU Therapeutics, Inc.
LEWISVILLE, Texas, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Qantu Therapeutics, Inc. announces the issuance of United States patent 10,195,257 titled “Vaccine Formulations Comprising Quillaja...